yes, that is a possibility. On the other hand if VYVGART treatment for CIDP patients from Argenx is accepted by the market within next two to three years, CSL will have to scramble around to find replacement revenue in many millions/billions.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$240.21 |
Change
1.500(0.63%) |
Mkt cap ! $116.3B | |||
| Open | High | Low | Value | Volume |
| $238.71 | $241.05 | $237.37 | $567.1M | 2.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1607 | $240.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $240.25 | 394 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| CSL (ASX) Chart |